Inuvair Nexthaler

Beclometasone dipropionate, the active ingredient in Inuvair Nexthaler, is an inhaled corticosteroid/long‑acting β2‑agonist presented as a dry powder inhaler for inhalation use. It is indicated for maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD) in adults and children, helping to control symptoms and reduce exacerbations.

GNH USA supplies Inuvair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑ready documentation for global distribution. This ensures reliable supply chains and timely delivery.

Inuvair Nexthaler combines an inhaled corticosteroid with a long‑acting β2‑agonist to provide maintenance therapy for obstructive airway diseases. - Asthma: improves airway inflammation control and reduces frequency of symptoms and exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances lung function, decreases breathlessness and lowers risk of exacerbations. - Chronic bronchitis: helps to reduce cough and sputum production associated with the chronic bronchitis component of COPD.

Inhalation of Inuvair Nexthaler may be associated with a range of adverse reactions, which are classified by frequency and severity. Common Side Effects: - Throat irritation: discomfort or soreness in the throat after inhalation. - Hoarseness: altered voice quality, often transient. - Oral candidiasis: fungal infection of the mouth, especially without rinsing. - Cough: mild to moderate coughing immediately after use. - Headache: mild headache reported by some patients. Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Adrenal suppression: reduced cortisol production with prolonged high‑dose use. - Severe allergic reaction: anaphylaxis, angioedema, or urticaria.

When prescribing or using Inuvair Nexthaler, several precautionary measures should be observed to ensure safety and optimal benefit. - Assess inhaler technique: verify patient can correctly load and inhale from the Nexthaler. - Monitor for oral thrush: advise rinsing mouth with water after each dose. - Use lowest effective dose: titrate to the minimum dose that controls symptoms. - Caution in cardiovascular disease: evaluate heart rate and blood pressure due to β2‑agonist effects. - Avoid abrupt discontinuation: taper dose under medical supervision to prevent loss of control. - Store at ambient temperature: keep the inhaler below 25 °C, in the original container, protected from moisture.

Inuvair Nexthaler may interact with other medicines; awareness of significant interactions helps to avoid reduced efficacy or increased risk. Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator response and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase systemic exposure to beclometasone. - Diuretics (e.g., furosemide): may potentiate hypokalemia when combined with formoterol. Moderate Interactions (Monitor Closely): - Theophylline: formoterol can raise plasma theophylline levels, requiring monitoring. - β‑agonist containing rescue inhalers: additive bronchodilator effect may increase cardiovascular side effects. - Anticholinergic bronchodilators: combined use may enhance bronchodilation but warrants observation for cough.